Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLY020
MIFTS: 44

Polyradiculoneuropathy

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Polyradiculoneuropathy

About this section

MalaCards integrated aliases for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 12 55 44 15 73

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4308
MeSH 44 D011129
UMLS 73 C0032587
Sources

Summaries for Polyradiculoneuropathy

About this section
MalaCards based summary : Polyradiculoneuropathy is related to chronic inflammatory demyelinating polyradiculoneuropathy and guillain-barre syndrome. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and brain, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Polyradiculoneuropathy

About this section

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 32.8 ALB HLA-DRB1 IFNG IL17A MPZ NFASC
2 guillain-barre syndrome 31.9 ALB MBP MPZ PMP2 PMP22
3 myasthenia gravis 30.1 IFNG IL10 MBP
4 viral infectious disease 30.0 CXCR4 IFNG IL10
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.9 IFNG IL10 IL17A
6 neurosyphilis 29.8 IL10 IL17A
7 systemic lupus erythematosus 29.8 ALB HLA-DRB1 IFNG IL10 IL17A
8 mixed connective tissue disease 29.8 HLA-DRB1 IFNG IL10
9 connective tissue disease 29.8 HLA-DRB1 IFNG IL10
10 chronic graft versus host disease 29.8 ALB IFNG IL10
11 graft-versus-host disease 29.7 HLA-DRB1 IFNG IL10
12 meningitis 29.7 ALB IFNG IL10
13 polyneuropathy 29.6 MAG MBP MPZ PMP22
14 autoimmune disease 29.6 HLA-DRB1 IFNG IL10 IL17A MBP
15 arthritis 29.5 HLA-DRB1 IFNG IL10 IL17A
16 neuritis 29.4 IFNG MAG MBP MPZ PMP2 PMP22
17 optic neuritis 29.4 HLA-DRB1 MAG MBP MPZ
18 malaria 29.3 ALB HLA-DRB1 IFNG IL10 IL17A
19 multiple sclerosis 29.2 HLA-DRB1 IFNG IL10 IL17A MAG MBP
20 polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies 12.0
21 chronic inflammatory demyelinating polyneuropathy 12.0
22 subacute inflammatory demyelinating polyneuropathy 11.5
23 lewis-sumner syndrome 11.4
24 guillain-barre syndrome, familial 11.3
25 chronic inflammatory demyelinating polyneuritis 11.2
26 chronic polyradiculoneuritis 11.1
27 x-linked charcot-marie-tooth disease 11.1
28 neuropathy 10.3
29 charcot-marie-tooth hereditary neuropathy 10.3 MPZ PMP22
30 foot drop 10.3 MPZ PMP22
31 roussy-levy hereditary areflexic dystasia 10.3 MPZ PMP22
32 charcot-marie-tooth disease, demyelinating, type 1f 10.3 MPZ PMP22
33 charcot-marie-tooth disease, axonal, type 2d 10.3 MPZ PMP22
34 charcot-marie-tooth disease, x-linked dominant, 1 10.3 MPZ PMP22
35 charcot-marie-tooth disease, demyelinating, type 1c 10.3 MPZ PMP22
36 neuropathy - hereditary 10.2 MPZ PMP22
37 berylliosis 10.2 HLA-DRB1 IFNG
38 chronic beryllium disease 10.2 HLA-DRB1 IFNG
39 charcot-marie-tooth disease, demyelinating, type 1b 10.2 MPZ PMP22
40 meningovascular neurosyphilis 10.2 ALB MBP
41 eosinophilia-myalgia syndrome 10.2 HLA-DRB1 IFNG
42 lupus erythematosus 10.2
43 charcot-marie-tooth disease, axonal, type 2b 10.2 MPZ PMP22
44 cephalosporin allergy 10.2 IFNG IL10
45 juvenile myasthenia gravis 10.2 HLA-DRB1 IL10
46 trichosporonosis 10.2 IFNG IL17A
47 hyperlucent lung 10.2 IFNG IL10
48 anteroseptal myocardial infarction 10.2 ALB HLA-DRB1
49 sporotrichosis 10.2 IFNG IL10
50 motor peripheral neuropathy 10.2 MPZ PMP22

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to Polyradiculoneuropathy
Sources

Symptoms & Phenotypes for Polyradiculoneuropathy

About this section

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 CNTN1 IFNG IL10 MAG MBP MPZ
2 cellular MP:0005384 10.11 ALB CNTN1 CXCR4 IFNG IL10 MBP
3 homeostasis/metabolism MP:0005376 10.1 ALB CXCR4 IFNG IL10 IL17A MAG
4 growth/size/body region MP:0005378 10.06 CNTN1 CXCR4 IFNG IL10 IL17A MBP
5 mortality/aging MP:0010768 10 ALB CNTN1 CXCR4 IFNG IL10 IL17A
6 hematopoietic system MP:0005397 9.97 CXCR4 IFNG IL10 IL17A MAG MBP
7 digestive/alimentary MP:0005381 9.91 ALB CNTN1 CXCR4 IFNG IL10 IL17A
8 nervous system MP:0003631 9.7 CNTN1 CXCR4 IFNG IL10 MAG MBP
9 muscle MP:0005369 9.63 ALB CNTN1 CXCR4 IFNG IL10 PMP22
10 reproductive system MP:0005389 9.17 CXCR4 IFNG IL10 MBP MPZ PMP22
Sources

Drugs & Therapeutics for Polyradiculoneuropathy

About this section

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Not Applicable
8
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
9
Mycophenolic acid Approved Phase 3 24280-93-1 446541
10
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
11 Immunosuppressive Agents Phase 3,Phase 2
12 Fingolimod Hydrochloride Phase 3
13 3,4-diaminopyridine Phase 3
14 Potassium Channel Blockers Phase 3,Phase 2
15 Anti-Inflammatory Agents Phase 3,Phase 2
16 Hormone Antagonists Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
18 glucocorticoids Phase 3,Phase 2
19 Hormones Phase 3,Phase 2
20 Antineoplastic Agents, Hormonal Phase 3,Phase 2
21 Pharmaceutical Solutions Phase 3,Phase 2
22 Anti-Infective Agents Phase 3,Phase 2
23 Antitubercular Agents Phase 3
24 Antibiotics, Antitubercular Phase 3
25 Anti-Bacterial Agents Phase 3
26
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
27
4-Aminopyridine Approved Phase 2 504-24-5 1727
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29 Complement System Proteins Phase 2
30 Interferon-beta Phase 2
31 Antiviral Agents Phase 2
32 Adjuvants, Immunologic Phase 2
33 interferons Phase 2
34 Antioxidants Phase 2
35 Vitamin B9 Phase 2
36 Vitamins Phase 2
37 Protective Agents Phase 2
38 Thioctic Acid Phase 2
39 Trace Elements Phase 2
40 Alpha-lipoic Acid Phase 2
41 Folate Phase 2
42 Vitamin B Complex Phase 2
43 Micronutrients Phase 2
44 Antirheumatic Agents Phase 2
45
Infliximab Approved 170277-31-3
46
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
47 4-des-dimethylaminotetracycline
48 Gastrointestinal Agents
49 Dermatologic Agents
50 Vaccines

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
5 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
6 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
7 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
9 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
11 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
12 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
13 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
14 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
15 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
16 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
17 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
18 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
19 Interest of Mycophenolate for CIDP Weaning Active, not recruiting NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
20 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
21 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
22 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
23 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
24 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
25 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
26 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
27 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
28 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
29 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
30 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
31 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
32 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
33 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
34 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
35 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
36 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
37 A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) Not yet recruiting NCT03773328 Phase 1
38 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
39 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
40 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858 Not Applicable
41 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
42 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
43 International Guillain-Barré Syndrome Outcome Study Unknown status NCT01582763
44 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
45 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
46 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
47 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
48 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
49 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
50 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937

Search NIH Clinical Center for Polyradiculoneuropathy

Cochrane evidence based reviews: polyradiculoneuropathy

Sources

Genetic Tests for Polyradiculoneuropathy

About this section
Sources

Anatomical Context for Polyradiculoneuropathy

About this section

MalaCards organs/tissues related to Polyradiculoneuropathy:

41
T Cells, Spinal Cord, Brain, Thyroid, Lung, Bone, B Cells
Sources

Publications for Polyradiculoneuropathy

About this section

Articles related to Polyradiculoneuropathy:

(show top 50) (show all 551)
# Title Authors Year
1
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 30266626 )
2019
2
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. ( 29554579 )
2018
3
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
4
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
5
Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. ( 29709940 )
2018
6
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. ( 29603842 )
2018
7
DEVELOPMENT OF GANGLIONOPATHY AND TABETIC VISCERAL CRISES ON THE BACKGROUND OF POLYRADICULONEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMOPATHY (CASE REPORT). ( 29578430 )
2018
8
Clinical Significance of A Waves in Acute Inflammatory Demyelinating Polyradiculoneuropathy. ( 29847438 )
2018
9
Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-BarrAc syndrome. ( 29801870 )
2018
10
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
11
Myelitis and Polyradiculoneuropathy With Severe Pain: Unusual Neurological Manifestations as Presenting Symptoms of Brucellosis. ( 29953037 )
2018
12
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
13
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
14
Immunohistochemistry and electrophysiological findings in swine abattoir workers with immune-mediated polyradiculoneuropathy. ( 29406910 )
2018
15
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29866282 )
2018
16
Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barré syndrome in India. ( 29053890 )
2018
17
Ischemic polyradiculoneuropathy with an aortic aneurysm masquerading Guillain-Barré syndrome. ( 30038123 )
2018
18
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
19
Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique. ( 29926221 )
2018
20
Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29999199 )
2018
21
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. ( 30001923 )
2018
22
Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. ( 30072201 )
2018
23
Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous T2 mapping and neurography method with SHINKEI. ( 30160180 )
2018
24
Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. ( 30203907 )
2018
25
Chronic inflammatory demyelinating polyradiculoneuropathy: A case report. ( 30313036 )
2018
26
The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis and the implications for treatment of acute inflammatory demyelinating polyradiculoneuropathy or Guillain-Barré syndrome. ( 30464413 )
2018
27
Acute Inflammatory Demyelinating Polyradiculoneuropathy Secondary to Ifosfamide. ( 28816726 )
2018
28
Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy? ( 30033838 )
2018
29
Subacute demyelinating polyradiculoneuropathy complicating Epstein-Barr virus infection in GATA2 haploinsufficiency. ( 28093780 )
2017
30
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
31
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
32
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
33
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
34
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
35
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
36
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
37
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
38
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
39
Early electrophysiological findings in acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barre syndrome in the Pakistani populationA -A a comparison with global data. ( 29091318 )
2017
40
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
41
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
42
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
43
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
44
Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors. ( 28432982 )
2017
45
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
46
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
47
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
48
Clinical Characteristics and Treatment Response of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29911781 )
2017
49
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
50
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
Sources

Variations for Polyradiculoneuropathy

About this section
Sources

Expression for Polyradiculoneuropathy

About this section
Search GEO for disease gene expression data for Polyradiculoneuropathy.
Sources

Pathways for Polyradiculoneuropathy

About this section

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 37
Show member pathways
 12.37 CXCR4 HLA-DRB1 IFNG IL10 IL17A PRF1
2
Th17 cell differentiation 37
Show member pathways
 12.35 HLA-DRB1 IFNG IL10 IL17A
3
Neuroscience 4
12.33 CXCR4 MAG MBP NFASC
4
NF-kappaB Signaling 4
12.29 CXCR4 IFNG IL10 IL17A
5
Th1 Differentiation Pathway 65
Show member pathways
 11.84 IFNG IL10 IL17A
6
Spinal Cord Injury 1
11.78 IFNG MAG MBP
7
Jak-Stat Signaling Pathway (sino) 67
11.66 CXCR4 IFNG IL10
8
Neural Crest Differentiation 1
11.64 MBP MPZ PMP22
9
Rheumatoid arthritis 37
11.56 HLA-DRB1 IFNG IL17A
10
Innate Lymphoid Cell Differentiation Pathways 65
11.48 IFNG IL10 IL17A
11
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.35 IFNG IL10 IL17A
12
Cell adhesion molecules (CAMs) 37
11.18 CNTN1 HLA-DRB1 MAG MPZ NFASC
13
OX40 Pathway 64
10.97 IFNG IL10
14
Cytokines and Inflammatory Response 1
10.9 HLA-DRB1 IFNG IL10
15
IL12 signaling mediated by STAT4 1
10.58 HLA-DRB1 IFNG PRF1
16
Glial Cell Differentiation 1
10.27 MAG MBP
Sources

GO Terms for Polyradiculoneuropathy

About this section

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.17 ALB CNTN1 MAG MBP MPZ NFASC
2 paranode region of axon GO:0033270 9.16 MAG NFASC
3 compact myelin GO:0043218 9.13 MAG MBP PMP22

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peripheral nervous system development GO:0007422 9.48 NFASC PMP22
2 positive regulation of interleukin-6 secretion GO:2000778 9.46 IL17A MBP
3 positive regulation of osteoclast differentiation GO:0045672 9.43 IFNG IL17A
4 immune response GO:0006955 9.43 CXCR4 HLA-DRB1 IFNG IL10 IL17A MBP
5 transmission of nerve impulse GO:0019226 9.4 MAG NFASC
6 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.37 MAG MPZ
7 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.32 IL10 MBP
8 positive regulation of interleukin-23 production GO:0032747 9.26 IFNG IL17A
9 positive regulation of killing of cells of other organism GO:0051712 9.16 IFNG PRF1
10 myelination GO:0042552 8.92 MBP MPZ NFASC PMP22

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.62 ALB PMP2
Sources

Sources for Polyradiculoneuropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....